Filing Flows › Coherus Oncology (CHRS) › Recalls, complaints & regulation
Coherus Oncology (CHRS): clinical trials
Coherus Oncology (CHRS) beyond its filings: 5 active clinical trials.
Coherus Oncology's latest quarter
Coherus Oncology, Q2 2026: revenue $14.3M (+40% year over year), operating margin -226.0%, net loss $20.6M, operating cash flow −$62.1M. The chart follows the revenue to costs, profit and cash.
Questions
How many clinical trials does Coherus Oncology have?
5 active studies on ClinicalTrials.gov, 0 in phase 3.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.